Focus Stock》Yaohua Yao: double benefits and multiple blessings, bucking the trend and becoming popular

[Reporter Chen Yongji/Report from Taipei] The Taiwan stock market plummeted by more than 3,700 points this morning, and some market funds were transferred into biotech stocks. Huayao (6446), the king of the biotech market in terms of market capitalization, yesterday announced a new high in October revenue. Therefore, although the stock price opened low today, buying orders immediately entered the market, and the stock price suddenly surged into the red, with the stock price fluctuating by more than 13%.

The stock price of Yaohua Pharmaceutical reached a low of 1,075 yuan in early trading. As of 10:12, the stock price was temporarily quoted at 1,245 yuan, an increase of 60 yuan, or 5%, with a trading volume of more than 3,200 contracts.

Due to the Democratic victory in the U.S. midterm elections, the market expects that Trump's policy of slashing drug prices or requiring pharmaceutical companies to set up factories in the United States may be discounted. Since Yaohua Pharmaceutical's new drugs are mainly sold in the U.S. market, the market is expected to benefit.

Yaohua announced yesterday that its revenue in October was 2.84 billion yuan, a monthly increase of 7.6% and an annual increase of 102.0%, setting a record high in a single month. This was mainly due to the steady growth of the core drug Ropeg in the polycythemia vera (PV) market. The Ropeg injection pen, which was launched in the United States in July this year, increased patients' willingness to use medication with a more convenient way of medication, driving double-digit sales growth in the U.S. market.